Titre :
|
Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. (1999)
|
Auteurs :
|
Morten LEBECH ;
O. ANDERSON ;
Niels CHRISTENSEN ;
et al. ;
Jens HERTEL
|
Type de document :
|
Article
|
Dans :
|
Lancet (The) (vol. 353, n° 9167, 1999/05/29)
|
Pagination :
|
1834-1837
|
Langues:
|
Anglais
|
Mots-clés :
|
Toxoplasmose
;
Anticorps
;
Dépistage
;
Prévention santé
;
Mère
;
Nouveau né
;
Danemark
|
Résumé :
|
The best method for prevention and control of congenital toxoplasma infection is uncertain. Prenatal screening is done in Austria and France, but the effect of treatment during pregnancy is not well documented. The aim of our study was to find out the maternofetal transmission rate and outcome in infants born to mothers who were not treated during pregnancy. Methods We analysed 89 873 eluates fom phenylketonuria (PKU) cards from neonates and paired first-trimester serum samples from the mothers who seroconverted during pregnancy were followed up clinically and serlogically to 12 months of age. In addition, 21 144 PKU cards were analysed for toxoplasma-specific IgM during the last 12 months of study (...) The risks of transmission of infection and of disease in the infant are low in an area with a low risk of toxoplasma infection. A neonatal screening programme based on detection of toxoplasma-specific IgM antibodies alone will identify between 70% and 80% of cases of congenital toxoplasmosis.
|